{"product_id":"semaglutide-10mg","title":"Semaglutide – 10 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eSemaglutide\u003c\/strong\u003e is the most extensively studied \u003cstrong\u003eGLP-1 receptor agonist\u003c\/strong\u003e — a single, highly selective incretin-pathway agonist that has become the reference standard against which newer dual and triple agonists are measured. It acts on appetite signaling, glucose-dependent insulin release and gastric emptying.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 68-week \u003cstrong\u003eSTEP 1\u003c\/strong\u003e obesity trial, participants on 2.4 mg recorded a mean \u003cstrong\u003ebody-weight reduction of 14.9%\u003c\/strong\u003e, versus 2.4% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e50%\u003c\/strong\u003e lost 15% or more of their body weight, and \u003cstrong\u003e69%\u003c\/strong\u003e lost at least 10%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eIts evidence base runs deep: in \u003cstrong\u003etype-2 diabetes\u003c\/strong\u003e (SUSTAIN 1) semaglutide cut HbA1c by \u003cstrong\u003e1.55 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e, and in the 17,604-patient \u003cstrong\u003eSELECT\u003c\/strong\u003e cardiovascular trial it reduced major cardiac events by \u003cstrong\u003e20%\u003c\/strong\u003e in adults with obesity and no diabetes\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2307563\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the semaglutide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816108998883,"sku":"SM10","price":90.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-glp-1sg-10-mg.png?v=1784484003","url":"https:\/\/qovigen.com\/products\/semaglutide-10mg","provider":"Qovigen Peptides","version":"1.0","type":"link"}